Pregabalin

Drug Profile

Pregabalin

Alternative Names: CI 1008; Isobutylgaba; Lyrica; PD 144723; Pregabalin oral solution

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Northwestern University
  • Developer Eisai Co Ltd; Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia
  • Phase III Tonic-clonic epilepsy
  • Discontinued Pain; Postoperative pain; Restless legs syndrome

Most Recent Events

  • 01 Dec 2016 Adverse events data from a phase III trial in Partial epilepsies (Adjuctive treatment, In adolescants, In children) released by Pfizer
  • 01 Dec 2016 Pfizer completes the phase III trial in Partial epilepsies (Adjunctive treatment, In adolescents, In children) in USA, Belgium, Hungary, Finland, Netherlands, Czech Republic, Sweden, Austria, Greece, Italy, Estonia, Bulgaria, Lithuania (PO) (EudraCT2010-020852-79) (NCT01389596)
  • 04 May 2016 Discontinued - Phase-III for Neuropathic pain in Puerto Rico, Colombia, South Korea (PO) (Pfizer pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top